Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169849224> ?p ?o ?g. }
- W3169849224 endingPage "1046" @default.
- W3169849224 startingPage "1034" @default.
- W3169849224 abstract "Background Most patients with ovarian cancer will relapse after receiving frontline platinum-based chemotherapy and eventually develop platinum-resistant or platinum-refractory disease. We report results of avelumab alone or avelumab plus pegylated liposomal doxorubicin (PLD) compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer. Methods JAVELIN Ovarian 200 was an open-label, parallel-group, three-arm, randomised, phase 3 trial, done at 149 hospitals and cancer treatment centres in 24 countries. Eligible patients were aged 18 years or older with epithelial ovarian, fallopian tube, or peritoneal cancer (maximum of three previous lines for platinum-sensitive disease, none for platinum-resistant disease) and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1:1) via interactive response technology to avelumab (10 mg/kg intravenously every 2 weeks), avelumab plus PLD (40 mg/m2 intravenously every 4 weeks), or PLD and stratified by disease platinum status, number of previous anticancer regimens, and bulky disease. Primary endpoints were progression-free survival by blinded independent central review and overall survival in all randomly assigned patients, with the objective to show whether avelumab alone or avelumab plus PLD is superior to PLD. Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02580058. The trial is no longer enrolling patients and this is the final analysis of both primary endpoints. Findings Between Jan 5, 2016, and May 16, 2017, 566 patients were enrolled and randomly assigned (combination n=188; PLD n=190, avelumab n=188). At data cutoff (Sept 19, 2018), median duration of follow-up for overall survival was 18·4 months (IQR 15·6–21·9) for the combination group, 17·4 months (15·2–21·3) for the PLD group, and 18·2 months (15·8–21·2) for the avelumab group. Median progression-free survival by blinded independent central review was 3·7 months (95% CI 3·3–5·1) in the combination group, 3·5 months (2·1–4·0) in the PLD group, and 1·9 months (1·8–1·9) in the avelumab group (combination vs PLD: stratified HR 0·78 [repeated 93·1% CI 0·59–1·24], one-sided p=0·030; avelumab vs PLD: 1·68 [1·32–2·60], one-sided p>0·99). Median overall survival was 15·7 months (95% CI 12·7–18·7) in the combination group, 13·1 months (11·8–15·5) in the PLD group, and 11·8 months (8·9–14·1) in the avelumab group (combination vs PLD: stratified HR 0·89 [repeated 88·85% CI 0·74–1·24], one-sided p=0·21; avelumab vs PLD: 1·14 [0·95–1·58], one-sided p=0·83]). The most common grade 3 or worse treatment-related adverse events were palmar-plantar erythrodysesthesia syndrome (18 [10%] in the combination group vs nine [5%] in the PLD group vs none in the avelumab group), rash (11 [6%] vs three [2%] vs none), fatigue (ten [5%] vs three [2%] vs none), stomatitis (ten [5%] vs five [3%] vs none), anaemia (six [3%] vs nine [5%] vs three [2%]), neutropenia (nine [5%] vs nine [5%] vs none), and neutrophil count decreased (eight [5%] vs seven [4%] vs none). Serious treatment-related adverse events occurred in 32 (18%) patients in the combination group, 19 (11%) in the PLD group, and 14 (7%) in the avelumab group. Treatment-related adverse events resulted in death in one patient each in the PLD group (sepsis) and avelumab group (intestinal obstruction). Interpretation Neither avelumab plus PLD nor avelumab alone significantly improved progression-free survival or overall survival versus PLD. These results provide insights for patient selection in future studies of immune checkpoint inhibitors in platinum-resistant or platinum-refractory ovarian cancer. Funding Pfizer and Merck KGaA, Darmstadt, Germany. Most patients with ovarian cancer will relapse after receiving frontline platinum-based chemotherapy and eventually develop platinum-resistant or platinum-refractory disease. We report results of avelumab alone or avelumab plus pegylated liposomal doxorubicin (PLD) compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer. JAVELIN Ovarian 200 was an open-label, parallel-group, three-arm, randomised, phase 3 trial, done at 149 hospitals and cancer treatment centres in 24 countries. Eligible patients were aged 18 years or older with epithelial ovarian, fallopian tube, or peritoneal cancer (maximum of three previous lines for platinum-sensitive disease, none for platinum-resistant disease) and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1:1) via interactive response technology to avelumab (10 mg/kg intravenously every 2 weeks), avelumab plus PLD (40 mg/m2 intravenously every 4 weeks), or PLD and stratified by disease platinum status, number of previous anticancer regimens, and bulky disease. Primary endpoints were progression-free survival by blinded independent central review and overall survival in all randomly assigned patients, with the objective to show whether avelumab alone or avelumab plus PLD is superior to PLD. Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02580058. The trial is no longer enrolling patients and this is the final analysis of both primary endpoints. Between Jan 5, 2016, and May 16, 2017, 566 patients were enrolled and randomly assigned (combination n=188; PLD n=190, avelumab n=188). At data cutoff (Sept 19, 2018), median duration of follow-up for overall survival was 18·4 months (IQR 15·6–21·9) for the combination group, 17·4 months (15·2–21·3) for the PLD group, and 18·2 months (15·8–21·2) for the avelumab group. Median progression-free survival by blinded independent central review was 3·7 months (95% CI 3·3–5·1) in the combination group, 3·5 months (2·1–4·0) in the PLD group, and 1·9 months (1·8–1·9) in the avelumab group (combination vs PLD: stratified HR 0·78 [repeated 93·1% CI 0·59–1·24], one-sided p=0·030; avelumab vs PLD: 1·68 [1·32–2·60], one-sided p>0·99). Median overall survival was 15·7 months (95% CI 12·7–18·7) in the combination group, 13·1 months (11·8–15·5) in the PLD group, and 11·8 months (8·9–14·1) in the avelumab group (combination vs PLD: stratified HR 0·89 [repeated 88·85% CI 0·74–1·24], one-sided p=0·21; avelumab vs PLD: 1·14 [0·95–1·58], one-sided p=0·83]). The most common grade 3 or worse treatment-related adverse events were palmar-plantar erythrodysesthesia syndrome (18 [10%] in the combination group vs nine [5%] in the PLD group vs none in the avelumab group), rash (11 [6%] vs three [2%] vs none), fatigue (ten [5%] vs three [2%] vs none), stomatitis (ten [5%] vs five [3%] vs none), anaemia (six [3%] vs nine [5%] vs three [2%]), neutropenia (nine [5%] vs nine [5%] vs none), and neutrophil count decreased (eight [5%] vs seven [4%] vs none). Serious treatment-related adverse events occurred in 32 (18%) patients in the combination group, 19 (11%) in the PLD group, and 14 (7%) in the avelumab group. Treatment-related adverse events resulted in death in one patient each in the PLD group (sepsis) and avelumab group (intestinal obstruction). Neither avelumab plus PLD nor avelumab alone significantly improved progression-free survival or overall survival versus PLD. These results provide insights for patient selection in future studies of immune checkpoint inhibitors in platinum-resistant or platinum-refractory ovarian cancer." @default.
- W3169849224 created "2021-06-22" @default.
- W3169849224 creator A5008233699 @default.
- W3169849224 creator A5010965225 @default.
- W3169849224 creator A5013784225 @default.
- W3169849224 creator A5014611244 @default.
- W3169849224 creator A5015984427 @default.
- W3169849224 creator A5021522674 @default.
- W3169849224 creator A5022758839 @default.
- W3169849224 creator A5025271372 @default.
- W3169849224 creator A5033072735 @default.
- W3169849224 creator A5037496681 @default.
- W3169849224 creator A5049348377 @default.
- W3169849224 creator A5057002841 @default.
- W3169849224 creator A5065447416 @default.
- W3169849224 creator A5072712459 @default.
- W3169849224 creator A5073063132 @default.
- W3169849224 creator A5073713547 @default.
- W3169849224 creator A5078857320 @default.
- W3169849224 creator A5079383798 @default.
- W3169849224 creator A5080823003 @default.
- W3169849224 creator A5086081284 @default.
- W3169849224 creator A5088144652 @default.
- W3169849224 date "2021-07-01" @default.
- W3169849224 modified "2023-10-14" @default.
- W3169849224 title "Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study" @default.
- W3169849224 cites W2039123767 @default.
- W3169849224 cites W2074546881 @default.
- W3169849224 cites W2107457010 @default.
- W3169849224 cites W2120426523 @default.
- W3169849224 cites W2124103653 @default.
- W3169849224 cites W2140492749 @default.
- W3169849224 cites W2162645859 @default.
- W3169849224 cites W2300386653 @default.
- W3169849224 cites W2410778127 @default.
- W3169849224 cites W2789502254 @default.
- W3169849224 cites W2796582438 @default.
- W3169849224 cites W2800654890 @default.
- W3169849224 cites W2801494416 @default.
- W3169849224 cites W2810283399 @default.
- W3169849224 cites W2884366738 @default.
- W3169849224 cites W2890261294 @default.
- W3169849224 cites W2892640821 @default.
- W3169849224 cites W2897283341 @default.
- W3169849224 cites W2897422388 @default.
- W3169849224 cites W2898424703 @default.
- W3169849224 cites W2911940503 @default.
- W3169849224 cites W2986633517 @default.
- W3169849224 doi "https://doi.org/10.1016/s1470-2045(21)00216-3" @default.
- W3169849224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34143970" @default.
- W3169849224 hasPublicationYear "2021" @default.
- W3169849224 type Work @default.
- W3169849224 sameAs 3169849224 @default.
- W3169849224 citedByCount "142" @default.
- W3169849224 countsByYear W31698492242021 @default.
- W3169849224 countsByYear W31698492242022 @default.
- W3169849224 countsByYear W31698492242023 @default.
- W3169849224 crossrefType "journal-article" @default.
- W3169849224 hasAuthorship W3169849224A5008233699 @default.
- W3169849224 hasAuthorship W3169849224A5010965225 @default.
- W3169849224 hasAuthorship W3169849224A5013784225 @default.
- W3169849224 hasAuthorship W3169849224A5014611244 @default.
- W3169849224 hasAuthorship W3169849224A5015984427 @default.
- W3169849224 hasAuthorship W3169849224A5021522674 @default.
- W3169849224 hasAuthorship W3169849224A5022758839 @default.
- W3169849224 hasAuthorship W3169849224A5025271372 @default.
- W3169849224 hasAuthorship W3169849224A5033072735 @default.
- W3169849224 hasAuthorship W3169849224A5037496681 @default.
- W3169849224 hasAuthorship W3169849224A5049348377 @default.
- W3169849224 hasAuthorship W3169849224A5057002841 @default.
- W3169849224 hasAuthorship W3169849224A5065447416 @default.
- W3169849224 hasAuthorship W3169849224A5072712459 @default.
- W3169849224 hasAuthorship W3169849224A5073063132 @default.
- W3169849224 hasAuthorship W3169849224A5073713547 @default.
- W3169849224 hasAuthorship W3169849224A5078857320 @default.
- W3169849224 hasAuthorship W3169849224A5079383798 @default.
- W3169849224 hasAuthorship W3169849224A5080823003 @default.
- W3169849224 hasAuthorship W3169849224A5086081284 @default.
- W3169849224 hasAuthorship W3169849224A5088144652 @default.
- W3169849224 hasBestOaLocation W31698492242 @default.
- W3169849224 hasConcept C121332964 @default.
- W3169849224 hasConcept C121608353 @default.
- W3169849224 hasConcept C126322002 @default.
- W3169849224 hasConcept C127413603 @default.
- W3169849224 hasConcept C142424586 @default.
- W3169849224 hasConcept C143998085 @default.
- W3169849224 hasConcept C207451115 @default.
- W3169849224 hasConcept C2776694085 @default.
- W3169849224 hasConcept C2777381376 @default.
- W3169849224 hasConcept C2777701055 @default.
- W3169849224 hasConcept C2780057760 @default.
- W3169849224 hasConcept C2780427987 @default.
- W3169849224 hasConcept C2780548848 @default.
- W3169849224 hasConcept C3019800554 @default.
- W3169849224 hasConcept C535046627 @default.
- W3169849224 hasConcept C71924100 @default.
- W3169849224 hasConcept C78519656 @default.
- W3169849224 hasConcept C87355193 @default.